BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31526390)

  • 1. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors.
    Zhang S; Yu S; Hou W; Li X; Ning C; Wu Y; Zhang F; Jiao YF; Lee LTO; Sun L
    J Ovarian Res; 2019 Sep; 12(1):87. PubMed ID: 31526390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
    Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
    Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of risk of malignancy indices; RMI 1-4 in borderline ovarian tumor.
    Yenen MC; Alanbay I; Aktürk E; Ercan CM; Coksuer H; Karaşahin E; Ozan H; Dede M
    Eur J Gynaecol Oncol; 2012; 33(2):168-73. PubMed ID: 22611957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pelvic masses score (PMS) and Risk of Malignancy Index (RMI 3) in the evaluation of pelvic masses.
    Rossi A; Forzano L; Romanello I; Ambrosini G; Iuri V; Marchesoni D
    Eur J Gynaecol Oncol; 2014; 35(4):421-4. PubMed ID: 25118484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ultrasound score, CA125, menopausal status, and risk of malignancy index in differentiating between benign and borderline or malignant ovarian tumors.
    Leelahakorn S; Tangjitgamol S; Manusirivithaya S; Thongsuksai P; Jaroenchainon P; Jivangkul C
    J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S22-30. PubMed ID: 17718292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
    Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
    Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound.
    Arun-Muthuvel V; Jaya V
    Asian Pac J Cancer Prev; 2014; 15(6):2929-32. PubMed ID: 24761927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
    Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
    J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.
    Anton C; Carvalho FM; Oliveira EI; Maciel GA; Baracat EC; Carvalho JP
    Clinics (Sao Paulo); 2012; 67(5):437-41. PubMed ID: 22666786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses.
    Morgante G; la Marca A; Ditto A; De Leo V
    Br J Obstet Gynaecol; 1999 Jun; 106(6):524-7. PubMed ID: 10426607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
    Moolthiya W; Yuenyao P
    Asian Pac J Cancer Prev; 2009; 10(5):865-8. PubMed ID: 20162854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
    Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
    Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
    Karlsen MA; Høgdall EV; Christensen IJ; Borgfeldt C; Kalapotharakos G; Zdrazilova-Dubska L; Chovanec J; Lok CA; Stiekema A; Mutz-Dehbalaie I; Rosenthal AN; Moore EK; Schodin BA; Sumpaico WW; Sundfeldt K; Kristjansdottir B; Zapardiel I; Høgdall CK
    Gynecol Oncol; 2015 Sep; 138(3):640-6. PubMed ID: 26086566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors.
    Minar L; Felsinger M; Cermakova Z; Zlamal F; Bienertova-Vasku J
    Int J Gynaecol Obstet; 2018 Feb; 140(2):241-246. PubMed ID: 29086914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses.
    Tingulstad S; Hagen B; Skjeldestad FE; Onsrud M; Kiserud T; Halvorsen T; Nustad K
    Br J Obstet Gynaecol; 1996 Aug; 103(8):826-31. PubMed ID: 8760716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Landolfo C; Achten ETL; Ceusters J; Baert T; Froyman W; Heremans R; Vanderstichele A; Thirion G; Van Hoylandt A; Claes S; Oosterlynck J; Van Rompuy AS; Schols D; Billen J; Van Calster B; Bourne T; Van Gorp T; Vergote I; Timmerman D; Coosemans A
    Gynecol Oncol; 2020 Dec; 159(3):811-819. PubMed ID: 32994054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
    Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
    J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.